Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
Overall survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).
1 finding from 1 review
Mycological cure · patients with tinea cruris and tinea corporis
Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).
1 finding from 1 review
Clinical cure · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes clinical cure (immediately at end of treatment) Resolution of… compared with moderate‐potent corticosteroid/azole combinations (very low certainty).
1 finding from 1 review
Adverse effects Reported by investigators 'and' or 'or' participants · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with moderate‐potent corticosteroid/azole combinations (very low certainty).
1 finding from 1 review
Relapse or recurrence Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Cure · patients with tinea cruris and tinea corporis
1 finding from 1 review
Duration of treatment until clinical cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
Antidepressants showed no clear difference in acceptability (all‐cause drop‐outs4) compared with a combination of medications (low certainty).
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review